These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9855564)

  • 1. Vigabatrin-associated retinal cone system dysfunction.
    Roubertie A; Bellet H; Echenne B
    Neurology; 1998 Dec; 51(6):1779-81. PubMed ID: 9855564
    [No Abstract]   [Full Text] [Related]  

  • 2. Vigabatrin-associated retinal cone system dysfunction.
    Brigell MG
    Neurology; 1998 Dec; 51(6):1779-81. PubMed ID: 9855563
    [No Abstract]   [Full Text] [Related]  

  • 3. Vigabatrin-associated retinal cone system dysfunction.
    Beck RW
    Neurology; 1998 Dec; 51(6):1778-9; author reply 1779-81. PubMed ID: 9855562
    [No Abstract]   [Full Text] [Related]  

  • 4. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings.
    Krauss GL; Johnson MA; Miller NR
    Neurology; 1998 Mar; 50(3):614-8. PubMed ID: 9521245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infantile spasms and vigabatrin. Visual field defects may be permanent.
    Lhatoo SD; Sander JW
    BMJ; 1999 Jan; 318(7175):57. PubMed ID: 10068225
    [No Abstract]   [Full Text] [Related]  

  • 6. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin.
    Ruether K; Pung T; Kellner U; Schmitz B; Hartmann C; Seeliger M
    Arch Ophthalmol; 1998 Jun; 116(6):817-9. PubMed ID: 9639460
    [No Abstract]   [Full Text] [Related]  

  • 7. Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication.
    Ponjavic V; Andréasson S
    Doc Ophthalmol; 2001 Jan; 102(1):63-72. PubMed ID: 11475366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptomatic and asymptomatic visual loss in patients taking vigabatrin.
    Daneshvar H; Racette L; Coupland SG; Kertes PJ; Guberman A; Zackon D
    Ophthalmology; 1999 Sep; 106(9):1792-8. PubMed ID: 10485552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin.
    Mackenzie R; Klistorner A
    BMJ; 1998 Jan; 316(7126):233. PubMed ID: 9468717
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing.
    Blackwell N; Hayllar J; Kelly G
    BMJ; 1997 Jun; 314(7095):1694. PubMed ID: 9193313
    [No Abstract]   [Full Text] [Related]  

  • 11. Severe persistent visual field constriction associated with vigabatrin.
    Eke T; Talbot JF; Lawden MC
    BMJ; 1997 Jan; 314(7075):180-1. PubMed ID: 9022432
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe persistent visual field constriction associated with vigabatrin. Benefit: risk ratio must be calculated for individual patients.
    Harding GF
    BMJ; 1998 Jan; 316(7126):232-3. PubMed ID: 9468716
    [No Abstract]   [Full Text] [Related]  

  • 13. Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist.
    Harding GF
    BMJ; 1997 Jun; 314(7095):1694. PubMed ID: 9193314
    [No Abstract]   [Full Text] [Related]  

  • 14. Severe persistent visual field constriction associated with vigabatrin. Manufacturers have started several studies.
    Backstrom JT; Hinkle RL; Flicker MR
    BMJ; 1997 Jun; 314(7095):1694-5. PubMed ID: 9193315
    [No Abstract]   [Full Text] [Related]  

  • 15. [Severe constriction of the visual field associated with vigabatrin discovered by thorough examination of a 17-year old girl].
    Roubergue A; Pelosse B; Doummar D; Beauvais P; Montchilova M; Gonthier B; Billette de Villemeur T
    Arch Pediatr; 1999 Aug; 6(8):901-2. PubMed ID: 10472407
    [No Abstract]   [Full Text] [Related]  

  • 16. Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent.
    Wong IC; Mawer GE; Sander JW
    BMJ; 1997 Jun; 314(7095):1693-4. PubMed ID: 9193312
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions.
    Wilson EA; Brodie MJ
    BMJ; 1997 Jun; 314(7095):1693. PubMed ID: 9193311
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of antiepileptic drugs on visual function, with special reference to Vigabatrin.
    Sorri I
    Acta Ophthalmol Scand; 2002 Jun; 80(3):343-4. PubMed ID: 12059879
    [No Abstract]   [Full Text] [Related]  

  • 19. Screening of patients taking vigabatrin.
    Rebolleda G; Muñoz-Negrete FJ; Gutierrez C
    Ophthalmology; 2000 Jul; 107(7):1219-20. PubMed ID: 10889083
    [No Abstract]   [Full Text] [Related]  

  • 20. GABA and the ornithine delta-aminotransferase gene in vigabatrin-associated visual field defects.
    Hisama FM; Mattson RH; Lee HH; Felice K; Petroff OA
    Seizure; 2001 Oct; 10(7):505-7. PubMed ID: 11749107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.